摩熵化学
数据库官网
小程序
打开微信扫一扫
首页 分子通 化学资讯 化学百科 反应查询 关于我们
请输入关键词

1-(2-phenoxyethyl)piperidine | 74-41-9

中文名称
——
中文别名
——
英文名称
1-(2-phenoxyethyl)piperidine
英文别名
1-Piperidino-2-phenoxyethane;1-(2-phenoxy-ethyl)-piperidine;1-(2-Phenoxy-aethyl)-piperidin;β-Phenoxyethylpiperidin;Phenyl-2-piperidinaethylaether;N-Piperidinoethylphenylether
1-(2-phenoxyethyl)piperidine化学式
CAS
74-41-9
化学式
C13H19NO
mdl
MFCD00454317
分子量
205.3
InChiKey
RSUFKEGMFFPMIB-UHFFFAOYSA-N
BEILSTEIN
——
EINECS
——
  • 物化性质
  • 计算性质
  • ADMET
  • 安全信息
  • SDS
  • 制备方法与用途
  • 上下游信息
  • 反应信息
  • 文献信息
  • 表征谱图
  • 同类化合物
  • 相关功能分类
  • 相关结构分类

计算性质

  • 辛醇/水分配系数(LogP):
    2.8
  • 重原子数:
    15
  • 可旋转键数:
    4
  • 环数:
    2.0
  • sp3杂化的碳原子比例:
    0.538
  • 拓扑面积:
    12.5
  • 氢给体数:
    0
  • 氢受体数:
    2

SDS

SDS:43d2468f03a92778bb46fda2856f5def
查看

上下游信息

  • 上游原料
    中文名称 英文名称 CAS号 化学式 分子量

反应信息

  • 作为反应物:
    描述:
    1-(2-phenoxyethyl)piperidine盐酸 作用下, 以 乙酸乙酯 为溶剂, 以915 mg的产率得到1-(2-phenoxyethyl)piperidine hydrochloride
    参考文献:
    名称:
    基于苯胺的H1N1流感病毒抑制剂对血凝素介导的融合的作用
    摘要:
    确定了两个易于获得的苯胺系列作为甲型流感病毒H1N1的抑制剂,并进行了广泛的化学合成和结构-活性关系的分析。该化合物显示可干扰由H1和H5(第1组)血凝素(HA)亚型介导的低pH诱导的膜融合。病毒抗性,HA相互作用和分子动力学模拟研究相结合,阐明了这些基于苯胺的流感融合抑制剂的结合位点,该位点与某些H3 HA特异性抑制剂所占据的口袋明显重叠,表明该腔与药物设计。
    DOI:
    10.1021/acs.jmedchem.7b00908
  • 作为产物:
    描述:
    4-溴苯酚正丁基锂potassium carbonate 作用下, 以 四氢呋喃正己烷丙酮 为溶剂, 反应 3.5h, 生成 1-(2-phenoxyethyl)piperidine
    参考文献:
    名称:
    四环杂化合物的合成作为选择性雌激素受体调节剂。第1部分。放大开发2,5,8取代的5,11-二氢色酚[4,3- c ]苯二甲基衍生物的工艺开发
    摘要:
    不对称的苯并吡喃并苯并吡喃化合物是新型的选择性雌激素受体调节剂(SERM)。开发了一种可重现的非色谱方法,以制备数百克数量的5-(4-(2-(2-哌啶-1-基)乙氧基)苯基)-5,11-二氢苯并[4,3 - c ]苯二甲基-2,8 -二基-双(2,2-二甲基丙酸酯)(14)。经过三个扩大规模的推广活动后,该11步合成的总产率从0.17%提高到7.1%。
    DOI:
    10.1021/op700020f
点击查看最新优质反应信息

文献信息

  • Mustard Carbonate Analogues as Sustainable Reagents for the Aminoalkylation of Phenols
    作者:Mattia Annatelli、Giacomo Trapasso、Claudio Salaris、Cristiano Salata、Sabrina Castellano、Fabio Aricò
    DOI:10.1002/ejoc.202100328
    日期:2021.6.25
    The nitrogen mustard gas moiety is present as a basic, amine-containing side chain in numerous pharmacophore scaffolds engaging in crucial interactions with targeted biological macromolecules. Herein, a one-pot synthetic approach for the easy introduction of nitrogen mustard-like moieties through dialkyl carbonate chemistry into different phenolic substrates is reported. The scope and limitations of
    氮芥气部分作为碱性含胺侧链存在于许多与靶向生物大分子进行关键相互作用的药效团支架中。本文报道了一种通过碳酸二烷基酯化学将氮芥样部分轻松引入不同酚类底物的一锅合成方法。已经研究了该反应作为酚类 -OH 基团的无氯直接取代的范围和局限性。
  • Aminoindazole derivatives
    申请人:Asahi Kasei Kogyo Kabushiki Kaisha
    公开号:US04533731A1
    公开(公告)日:1985-08-06
    A compound of the formula (I): ##STR1## wherein W.sub.1 and W.sub.2 each independently is a hydrogen atom or a ##STR2## group wherein Y is a n-C.sub.1-6 alkylene group or a n-C.sub.1-6 alkylene group having a C.sub.1-6 alkyl group substituent; and R.sub.1 and R.sub.2 each independently is a hydrogen atom or a C.sub.1-6 alkyl group, and ##STR3## group in ##STR4## group may form a saturated heterocyclic ring selected from the group consisting of morpholino, pyrrolidino, piperidino, homopiperidino and piperazino groups, and the saturated heterocyclic ring except the morpholino group may have at least one C.sub.1-4 alkyl group, hydroxyl group or halogen atom as a substituent; Z.sub.1 is a hydrogen atom, a chlorine atom, a bromine atom, an iodine atom, a hydroxyl group, an amino group, a C.sub.1-3 alkyl group or a methoxy group; Z.sub.2 is a hydrogen atom or an amino group; when W.sub.1 and W.sub.2 are both hydrogen atoms, Z.sub.1 is a hydroxyl group or an iodine atom and Z.sub.2 is hydrogen atom, or Z.sub.1 and Z.sub.2 are both amino groups; when Z.sub.1 and Z.sub.2 are both hydrogen atoms, the ##STR5## group in either W.sub.1 or W.sub.2 is a morpholino group; when Z.sub.1 is a chlorine atom, a hydroxyl group, an iodine atom, a methyl group or a methoxy group, Z.sub.2 is a hydrogen atom; when Z.sub.1 is an amino group, Z.sub.2 is a hydrogen atom or an amino group; when Z.sub.1 is a methyl group, a methoxy group or an amino group, Z.sub.1 is in the 5-position; when Z.sub.1 is an iodine atom, Z.sub.1 is in the 5- or 7-position; and when Z.sub.1 and Z.sub.2 are both amino groups, Z.sub.1 and Z.sub.2 are in the 5- and 7-positions; and the physiologically acceptable acid addition salt thereof which compounds have pharmaceutical utility, e.g.: treating inflammation.
    式(I)的化合物:其中W.sub.1和W.sub.2各自独立地是氢原子或##STR2##基团,其中Y是n-C.sub.1-6烷基烯基或具有C.sub.1-6烷基基团取代物的n-C.sub.1-6烷基烯基;R.sub.1和R.sub.2各自独立地是氢原子或C.sub.1-6烷基基团,以及##STR3##在##STR4##基团中的基团可能形成从吗啡啉,吡咯啉,哌啶,环己哌啶和哌嗪基团中选择的饱和杂环环;除了吗啡啉基团之外的饱和杂环环可能具有至少一个C.sub.1-4烷基基团,羟基基团或卤原子作为取代物;Z.sub.1是氢原子,氯原子,溴原子,碘原子,羟基,氨基,C.sub.1-3烷基基团或甲氧基基团;Z.sub.2是氢原子或氨基;当W.sub.1和W.sub.2都是氢原子时,Z.sub.1是羟基或碘原子,Z.sub.2是氢原子,或Z.sub.1和Z.sub.2都是氨基;当Z.sub.1和Z.sub.2都是氢原子时,W.sub.1或W.sub.2中的##STR5##基团是吗啡啉基团;当Z.sub.1是氯原子,羟基,碘原子,甲基基团或甲氧基基团时,Z.sub.2是氢原子;当Z.sub.1是氨基时,Z.sub.2是氢原子或氨基;当Z.sub.1是甲基基团,甲氧基基团或氨基时,Z.sub.1在5-位;当Z.sub.1是碘原子时,Z.sub.1在5-位或7-位;当Z.sub.1和Z.sub.2都是氨基时,Z.sub.1和Z.sub.2在5-位和7-位;以及其生理上可接受的酸盐,这些化合物具有药用价值,例如:用于治疗炎症。
  • [EN] PHENOXYETHYL PIPERIDINE COMPOUNDS<br/>[FR] COMPOSÉS PHÉNOXYÉTHYL PIPÉRIDINE
    申请人:LILLY CO ELI
    公开号:WO2014004229A1
    公开(公告)日:2014-01-03
    The present invention provides a compound of the Formula II: Formula II wherein X is: R1 is H, -CN, or F; R2 is H or methyl; R3 is H; and R4 is H, methyl, or ethyl; or R3 and R4 joined together form a cyclopropyl ring; or a pharmaceutically acceptable salt thereof.
    本发明提供了一种化合物,其化学式为II:其中X为:R1为H,-CN或F;R2为H或甲基;R3为H;R4为H,甲基或乙基;或者R3和R4结合在一起形成一个环丙基环;或其药用盐。
  • 3-Aminoindazole derivatives
    申请人:Asahi, Kasei, Kogyo, Kabushiki, Kaisha
    公开号:US04474964A1
    公开(公告)日:1984-10-02
    A compound of the formula (I): ##STR1## wherein W.sub.1 is a hydrogen atom or a ##STR2## group wherein Y is a C.sub.1-6 alkylene group or a C.sub.1-6 alkylene group having a C.sub.1-6 alkyl group substituent; and R.sub.1 and R.sub.2 each independently is a hydrogen atom or a C.sub.1-6 alkyl group and R.sub.1 and R.sub.2 may form a C.sub.4-6 heterocyclic ring or a nitrogen-containing C.sub.4-6 heterocyclic ring together with the adjacent nitrogen atom and the C.sub.4-6 heterocyclic rings may have at least one C.sub.1-6 alkyl group, hydroxyl group or halogen atom; W.sub.2 is a hydrogen atom or a ##STR3## group wherein Z is a C.sub.1-6 alkylene group or a C.sub.1-6 alkylene group having a C.sub.1-6 alkyl group substituent; and R.sub.3 and R.sub.4 each independently is a hydrogen atom or a C.sub.1-6 alkyl group and R.sub.3 and R.sub.4 may form a C.sub.4-6 heterocyclic ring or a nitrogen-containing C.sub.4-6 heterocyclic ring together with the adjacent nitrogen atom and the C.sub.4-6 heterocyclic rings may have at least one C.sub.1-6 alkyl group, hydroxyl group or halogen atom; when W.sub.1 is a hydrogen atom, W.sub.2 is the ##STR4## group; and when W.sub.2 is a hydrogen atom, W.sub.1 is the ##STR5## group; and the pharmaceutically acceptable acid addition salt thereof having antiinflammatory, analgesic and digestive tract ulcer suppressing activity.
    该化合物的结构式为:##STR1##其中W.sub.1是氢原子或##STR2##基团,其中Y是C.sub.1-6烷基烯基或具有C.sub.1-6烷基烯基取代基的C.sub.1-6烷基烯基;R.sub.1和R.sub.2各自独立地是氢原子或C.sub.1-6烷基基团,且R.sub.1和R.sub.2可以与相邻氮原子一起形成C.sub.4-6杂环环或含氮C.sub.4-6杂环环,且C.sub.4-6杂环环可能至少有一个C.sub.1-6烷基基团、羟基或卤原子;W.sub.2是氢原子或##STR3##基团,其中Z是C.sub.1-6烷基烯基或具有C.sub.1-6烷基烯基取代基的C.sub.1-6烷基烯基;R.sub.3和R.sub.4各自独立地是氢原子或C.sub.1-6烷基基团,且R.sub.3和R.sub.4可以与相邻氮原子一起形成C.sub.4-6杂环环或含氮C.sub.4-6杂环环,且C.sub.4-6杂环环可能至少有一个C.sub.1-6烷基基团、羟基或卤原子;当W.sub.1是氢原子时,W.sub.2是##STR4##基团;当W.sub.2是氢原子时,W.sub.1是##STR5##基团;及其具有抗炎、镇痛和抑制消化道溃疡活性的药用酸盐。
  • Synthesis of Tetracyclic Heterocompounds as Selective Estrogen Receptor Modulators. Part 2. Process Improvement for Scale-Up Of 2,5,8-Substituted 11,12-Dihydro-5<i>H</i>-6,13-dioxabenzo[3,4]cyclohepta-[1,2-<i>a</i>]naphthalene Derivatives
    作者:Xun Li、Michael Reuman、Ronald K. Russell、Scott Youells、Sandra Beish、Zhiyong Hu、Shawn Branum、Nareshkumar Jain、Zhihua Sui
    DOI:10.1021/op700061x
    日期:2007.7.1
    An improved, reproducible nonchromatographic process for scale-up synthesis of 2,5,8-substituted 11,12-dihydro-5H-6,13-dioxabenzo[3,4]cyclohepta[1,2-a]naphthalene derivatives as selective estrogen receptor modulators (SERMs) is described. The titled compounds were prepared in 9−21% overall yield with high chemical purity (>97%) after nine consecutive synthetic steps.
    一种改进的,可重现的非色谱方法,用于大规模合成2,5,8-取代的11,12-二氢-5 H -6,13-​​二氧杂苯并[3,4]环庚[1,2- a ]萘衍生物描述了雌激素受体调节剂(SERM)。经过九个连续的合成步骤,以9-21%的总收率制备了标题化合物,具有较高的化学纯度(> 97%)。
查看更多